[go: up one dir, main page]

WO2011040770A2 - Composition cosmétique de prévention de vieillissement et décolorante - Google Patents

Composition cosmétique de prévention de vieillissement et décolorante Download PDF

Info

Publication number
WO2011040770A2
WO2011040770A2 PCT/KR2010/006668 KR2010006668W WO2011040770A2 WO 2011040770 A2 WO2011040770 A2 WO 2011040770A2 KR 2010006668 W KR2010006668 W KR 2010006668W WO 2011040770 A2 WO2011040770 A2 WO 2011040770A2
Authority
WO
WIPO (PCT)
Prior art keywords
yeast extract
composition
skin
present
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/006668
Other languages
English (en)
Korean (ko)
Other versions
WO2011040770A3 (fr
Inventor
김동현
박준성
이성훈
이재경
김한곤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of WO2011040770A2 publication Critical patent/WO2011040770A2/fr
Publication of WO2011040770A3 publication Critical patent/WO2011040770A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to a composition containing the yeast extract as an active ingredient, and relates to a composition that exhibits an anti-aging and whitening effect such as collagen degradation by containing an extract of the yeast itself.
  • Human skin is changed by a number of internal and external factors as it ages. That is, internally, the secretion of various hormones that regulate metabolism decreases, and the function of immune cells and the activity of cells decreases, thereby reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms. Due to the increase in the amount of ultraviolet rays reaching the surface of the sun's rays and further increase environmental pollution, free radicals and free radicals, such as free radicals, skin thickness, wrinkles, elasticity is reduced only In addition, the color of the skin becomes dull, skin problems frequently occur, and blemishes, freckles, and mushrooms are also increasing.
  • cyclooxygenase-2 (Cox-2), an enzyme that produces proinflammatory cytokine, known to cause inflammation in most of the cells that make up skin, , the biosynthesis of cyclooxygenase increases, the biosynthesis of matrix metalloproteinase (MMP), an enzyme that breaks down skin tissues by these inflammatory factors, increases NO (nitric oxide) by inducible nitric oxide synthase (iNOS) Production is known to increase.
  • MMP matrix metalloproteinase
  • NO nitric oxide
  • iNOS inducible nitric oxide synthase
  • melanocytes that make melanin pigment
  • the distribution of blood vessels the thickness of the skin
  • pigments such as carotenoids, bilirubin, etc.
  • melanin a black pigment which is produced by the action of various enzymes such as tyrosinase in melanocytes in the human body.
  • the formation of this melanin pigment is influenced by genetic factors, physiological factors related to hormone secretion, stress, and environmental factors such as ultraviolet irradiation.
  • Melanin pigment which is produced from melanocytes of the skin of the body, is a phenolic polymer material having a complex form of black pigment and protein. It protects skin organs below the dermis by blocking ultraviolet rays from the sun and free radicals generated in the skin body. It plays a useful role in protecting proteins and genes in the skin.
  • melanin produced by stress stimulation inside and outside the skin is a stable substance that does not disappear until it is discharged to the outside through skin keratinization even if the stress disappears.
  • it causes hyperpigmentation such as blemishes, freckles, and spots, resulting in cosmetically bad results.
  • the leisure population increases, the number of people who enjoy being active outside increases the demand to prevent melanin pigmentation caused by ultraviolet rays.
  • ascorbic acid In response to such demands, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione or derivatives thereof, or substances having tyrosinase inhibitory activity have been used in combination with cosmetics or medicines. Its use is limited due to insufficient whitening effect, safety problems on skin, formulation and stability problems when formulated in cosmetics, and the like.
  • the inventors of the present invention through repeated and various experiments, confirmed that the yeast extract can provide a safe and sufficient anti-aging and whitening effect on the skin, and completed the present invention.
  • an object of the present invention is to provide an anti-aging and whitening composition containing the yeast extract.
  • the present invention provides a cosmetic composition and health food composition containing a yeast extract as an active ingredient.
  • composition according to the present invention exhibits an anti-aging effect and suppresses the production and degradation of collagen, and thus can be variously used in cosmetics, health food or medicine.
  • Figure 1 shows the result of measuring the yeast extract and kojic acid by HPLC.
  • Figure 2 shows the measurement results for koji acid and koji extract by overlapping the results of FIG.
  • the present invention relates to a composition containing the yeast extract as an active ingredient.
  • the leaven used in the present invention generally means leaven used for making makgeolli (Takju).
  • the method for preparing the yeast extract is not particularly limited, and may be obtained by extracting and filtering the yeast to obtain a filtrate, and then concentrating it.
  • the yeast extraction process of the present invention can be carried out by conventional methods known in the art. For example, water or an organic solvent may be added to Nuruk, reflux extraction is performed, and the residue and the filtrate are separated by filtration and centrifugation. The separated filtrate is concentrated under reduced pressure to obtain a Nuruk extract.
  • the organic solvent usable in the present invention may be selected from ethanol, methanol, butanol, ether, ethyl acetate, chloroform or a mixed solvent of these organic solvents and water, and preferably 80% ethanol is used.
  • the extraction temperature is preferably 10 ⁇ 80 °C
  • the extraction time is preferably 6 ⁇ 24 hours. If the extraction temperature and the extraction time is out of the extraction efficiency may be lowered or a change of components may occur.
  • Nuruk extract used as an active ingredient in the present invention promotes the production of collagen to provide an anti-aging effect by mitigating the reduction of collagen caused by aging of the human skin.
  • the yeast extract may provide an excellent skin whitening effect by inhibiting the production of melanin.
  • the composition of the present invention may be an external composition for skin, and more specifically, may be an anti-aging and whitening composition.
  • the content of the yeast extract contained in the composition is not particularly limited. Specifically, the yeast extract of the present invention may be contained in an amount of 0.001 to 90% by weight based on the total weight of the composition, preferably 0.01 to 30% by weight, more preferably 0.1 to 10% by weight.
  • the content range of the yeast extract is to select a preferred range that can improve the anti-aging effect and whitening effect.
  • the external composition for skin in the form of cosmetics, such as softening cosmetics, astringent cosmetics, nourishing cosmetics, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence or pack It may be formulated in a form, the formulation is not particularly limited.
  • cosmetics such as softening cosmetics, astringent cosmetics, nourishing cosmetics, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence or pack It may be formulated in a form, the formulation is not particularly limited.
  • composition according to the present invention may be a health food composition or a pharmaceutical composition.
  • the health food composition may be formulated in various forms such as powders, granules, tablets, capsules and drinks.
  • the said health food composition can be mix
  • various fruits concentrated juice, powder juice, etc.
  • Vitamins remithol palmitate, riboflavin, pyridoxine, cyanocobalamine, sodium ascorbate, nicotinic acid amide, calcium pantothenate, folic acid, biotin, cholecalciferol, cholinergic acid choline, tocopherol, ⁇ Water-soluble and fat-soluble vitamins such as carotene);
  • Flavorings lemon flavor, orange flavor, strawberry flavor, grapefruit flavor, vanilla essence, etc.
  • Amino acids, nucleic acids and salts thereof glutlutamic acid, sodium glutamate, glycine, alanine, aspartic acid, sodium aspartate, inos
  • the pharmaceutical composition may further contain pharmaceutical aids such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts for regulating osmotic pressure and / or buffers, and other therapeutically useful substances, and various oral agents in accordance with conventional methods. Or in parenteral dosage forms.
  • pharmaceutical aids such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts for regulating osmotic pressure and / or buffers, and other therapeutically useful substances, and various oral agents in accordance with conventional methods. Or in parenteral dosage forms.
  • Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These formulations may contain diluents (e.g., lactose, dextrose, Sucrose, mannitol, sorbitol, cellulose and glycine), lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols.
  • diluents e.g., lactose, dextrose, Sucrose, mannitol, sorbitol, cellulose and glycine
  • lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols.
  • Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners. Tablets may be prepared by conventional mixing, granulating or coating methods.
  • formulations for parenteral administration include external skin preparations, injections and the like, ointment is preferred as an external preparation for skin, may be an isotonic aqueous solution or suspension in the injection formulation.
  • Determination of the dosage of the active ingredient is within the level of those skilled in the art, and the daily dose of the drug according to the present invention depends on various factors such as the progression of symptoms, onset time, age, health condition, complications, etc. of the subject to be administered. Although based on an adult, generally 1 to 500 mg / kg of the composition, preferably 30 to 200 mg / kg, which is combined in the above-mentioned weight ratio, may be administered once or twice a day. Does not limit the scope of the invention in any way.
  • the content of the Nuruk extract in the health food composition or pharmaceutical composition is not particularly limited, but may be contained in the range of 10 to 90% by weight, preferably 20 to 50% by weight based on the total weight of the composition. This is in consideration of the fact that the content of the powder and the functional ingredient may be 10 to 60% by weight in the manufacture of tablets and soft capsules, and the content of the powder and the functional ingredient may be 10 to 90% by weight in the manufacture of hard capsules.
  • Kojic acid and koji extract of Example 1 were measured by HPLC (High Performance Liquid Chromatography, Varian, USA) in order to compare kojiic acid (kojic acid, purchased through YM chemical) and the yeast extract of the present invention. Comparing the HPLC results of kojic acid and koji extract by applying the same analysis conditions, it is possible to determine the presence or absence of kojic acid component. The results are shown in FIGS. 1 and 2.
  • the koji extract and kojic acid has a difference in the position where the peak (peak), respectively.
  • the yeast extract used in the present invention does not have kojic acid, and it can be confirmed that they are different materials from each other.
  • Human normal fibroblasts were cultured in a 12-hole plate incubator at a concentration of 10 5 , and then the yeast extract obtained in Example 1 was replaced with a medium containing the concentrations of 1 ppm, 10 ppm, and 50 ppm.
  • As a positive control one containing TGF- ⁇ (Human Transforming Growth Factor- ⁇ 1, Roche Co.) at a concentration of 10 ng / ml was used, and one containing no yeast extract and TGF- ⁇ was used as a negative control.
  • Cells were harvested on the third day of culture (harvest) to quantify the amount of type I procollagen produced by ELISA method. The amount of procollagen of the negative control group was set to 0 and the amount of procollagen of the positive control group was set to 100, and the comparison with each measured value was calculated. The results are shown in Table 1 below.
  • the Nuruk extract in the normal human fibroblast monolayer culture system promoted type I procollagen production in a concentration-dependent manner compared to the negative control. Therefore, the yeast extract of the present invention can be confirmed that by promoting collagen production to alleviate the reduction of collagen caused by aging of the human skin can provide an excellent anti-aging effect.
  • Mel-Ab cells derived from C57BL / 6 mice (Dooley, TP et al, Skin pharmacol, 7, pp 188-200) in DMEM with 10% fetal placental serum, 100 nM 12-O-tetradecanoyl Incubated at 37 ° C. and 5% CO 2 in a medium to which phorbol (tetradecanoylphorbol) -13-acetate and 1 nM cholera toxin were added.
  • the cultured Mel-Ab cells were detached with 0.25% trypsin-EDTA, the cells were incubated at a concentration of 10 5 cells / well in 24-well plates, and then each test material was added for 3 consecutive days. And incubated.
  • hydroquinone and the Nuruk extract of Example 1 were used at a concentration of 10 ppm. At this time, the hydroquinone was used as a positive control group. Then, the culture solution was removed, washed with PBS, and dissolved in 1N sodium hydroxide to measure absorbance at 400 nm, and then the melanin production inhibition rate was calculated according to Equation 1 shown in Table 2 (Dooley). Method).
  • yeast extract of the present invention shows melanin production inhibition similar to that of hydroquinone, which is a known whitening substance.
  • the degree of irritation such as stinging, itching, and eye aspiration in 15 panel sensitive to irritation such as stinging, burning, etc. was tested.
  • the yeast extract used in the present invention can be confirmed that there is no irritation as a substance different from kojic acid can provide better usability.
  • Yeast extract 80mg, vitamin E 9mg, vitamin C 9mg, palm oil 2mg, vegetable hardened oil 8mg, lead 4mg and lecithin 9mg were mixed and mixed according to a conventional method to prepare a soft capsule filling solution. 400 mg per capsule was filled to prepare a soft capsule.
  • a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filling solution, thereby preparing a soft capsule containing 400 mg of the composition according to the present invention.
  • Yeast extract 80mg, vitamin E 9mg, vitamin C 9mg, galactooligosaccharide 200mg, lactose 60mg and malt sugar 140mg were mixed, granulated using a fluidized bed dryer, and then 6mg sugar ester was added. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.
  • Nuruk extract 80mg, vitamin E 9mg, vitamin C 9mg, glucose 10g, citric acid 0.6g, and 25g of liquid oligosaccharides were mixed and 300ml of purified water was added to each bottle to 200ml. After filling the bottle sterilized for 4 to 5 seconds at 130 °C to prepare a beverage.
  • the yeast extract 80mg, vitamin E 9mg, vitamin C 9mg, anhydrous glucose of 250mg and starch 550mg were mixed, molded into granules using a fluidized bed granulator, and then filled into sachets.
  • Nutritional longevity was prepared according to the conventional composition described in Table 4 below.
  • Nutritional cream was prepared in a conventional manner according to the composition described in Table 5.
  • Table 5 ingredient Content (% by weight) Yeast Extract 5.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG60 Cured Castor Oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / Capric Triglycerides 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
  • Table 6 ingredient Content (% by weight) Yeast Extract 5.0 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 PEG60 Cured Castor Oil 2.0 Liquid paraffin 40.0 Squalane 5.0 Caprylic / Capric Triglycerides 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
  • the ointment was prepared in a conventional manner according to the composition described in Table 8.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition contenant de l'extrait de levure comme principe actif, et une composition à effet de prévention de vieillissement de type collagénolyse et effet décolorant par incorporation d'extrait de levure proprement dit.
PCT/KR2010/006668 2009-10-01 2010-09-30 Composition cosmétique de prévention de vieillissement et décolorante Ceased WO2011040770A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090093882A KR20110036299A (ko) 2009-10-01 2009-10-01 누룩 추출물을 함유하는 항노화 및 미백용 화장료 조성물
KR10-2009-0093882 2009-10-01

Publications (2)

Publication Number Publication Date
WO2011040770A2 true WO2011040770A2 (fr) 2011-04-07
WO2011040770A3 WO2011040770A3 (fr) 2011-10-06

Family

ID=43826795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006668 Ceased WO2011040770A2 (fr) 2009-10-01 2010-09-30 Composition cosmétique de prévention de vieillissement et décolorante

Country Status (2)

Country Link
KR (1) KR20110036299A (fr)
WO (1) WO2011040770A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101715194B1 (ko) 2015-04-17 2017-03-10 주식회사 뉴앤뉴 누룩으로부터 코직산 발현 및 농축추출방법
KR102674771B1 (ko) * 2021-07-14 2024-06-14 주식회사 바이오솔루션 고상발효 앉은뱅이밀 누룩의 발효 추출물을 포함하는 피부상태 개선용 화장료 조성물 및 식품 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514506B1 (en) * 2001-02-14 2003-02-04 Color Access, Inc. Whitening compositions containing ascomycete derived enzyme
JP3806419B2 (ja) * 2003-06-09 2006-08-09 日本コルマー株式会社 化粧料
US7320797B2 (en) * 2003-08-29 2008-01-22 Bioderm Research Antiaging cosmetic delivery systems

Also Published As

Publication number Publication date
WO2011040770A3 (fr) 2011-10-06
KR20110036299A (ko) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
US9364423B2 (en) Whitening agent, anti-aging agent, and antioxidant agent
KR102343112B1 (ko) 기능성 펩타이드, 아미노산, 캘러스 추출물 및 발효물을 포함하는 항노화 조성물
EP3130331A1 (fr) Inhibiteur de vieillissement de la peau et concentré de resvératrol 3-o- -glucoside
US20080206175A1 (en) Composition for Skin Whitening and Wrinkle Improvement Comprising Vaccinium Uliginosum Extract and Method for Preparation Thereof
WO2023113111A1 (fr) Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau
KR102809560B1 (ko) 개다래 추출물을 포함하는 피부 손상 개선용 또는 피부 보습용 조성물
EP3851095A1 (fr) Utilisation d'extrait de combretum micranthum dans des produits cosmétiques
WO2011019174A2 (fr) Composition ayant des effets antioxydants et blanchissants contenant un concentré d’alcool de riz coréen
WO2011115061A1 (fr) Promoteur de la production d'acide hyaluronique
KR101655146B1 (ko) 식물 당단백질 추출물을 함유하는 조성물
JP2003171300A (ja) メラニン生成抑制剤
WO2011040770A2 (fr) Composition cosmétique de prévention de vieillissement et décolorante
WO2016010283A1 (fr) Composition contenant de l'huile de glycine gracilis
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
KR20110101308A (ko) 관중 추출물을 함유하는 피부 미백용 화장료 조성물
KR102688578B1 (ko) 피부 개선용 조성물
KR102014961B1 (ko) 콩꼬투리 추출물을 함유하는 항산화용 조성물
KR102202729B1 (ko) 안토시아닌-폴리사카라이드 복합체를 유효성분으로 포함하는, 노화 또는 노화 관련 질환 예방 또는 치료용 약학적 조성물
KR102163882B1 (ko) 인삼 추출물과 녹차 추출물을 함유하는 피부 미백용 조성물
KR102650192B1 (ko) 스노우베리 과육을 포함하는 화장료 조성물 및 이의 제조방법
KR101698924B1 (ko) 식물 당단백질 추출물을 함유하는 조성물
WO2024014663A1 (fr) Composition pharmaceutique destinée à prévenir ou à traiter l'alopécie comprenant de l'akkermansia
KR102087650B1 (ko) 인삼 다당체와 녹차 다당체를 함유하는 피부 미백용 조성물
KR102014960B1 (ko) 콩뿌리 추출물을 함유하는 항산화용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10820843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10820843

Country of ref document: EP

Kind code of ref document: A2